Anteris Technologies Global Corp. (AVR)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$9.04+3.67%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · AVR
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 204.0% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is on a run of consecutive earnings misses and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 87 industry peers · Company calendar date is not available
AVR — earnings miss
Dated 2026-08-12
Results of Operations and Financial Condition. On August 11, 2026 USA ET (August 12, 2026 AEST), Anteris Technologies Global Corp. (the “Company”) (i) filed the Form 10-Q for the quarter ended June 30, 2026 with a cover page (the “Results Announcement”) with the Australian Securities Exchange (“ASX”); and (ii) issued an ASX Announcement regarding the Company’s financial results for the quarter ended June 30, 2026, both of which include unaudited and other historical financial information for…
Why it matters: More money raised could show financial health. It may help the PARADIGM Trial.
Supportive ifAnteris will raise over $100 million by Q4 2026.
Worry ifNo new capital raises or indications of financial strain by Q4 2026.
Why it matters: More patients enrolled in the trial shows strong execution and supports future revenue.
Supportive ifU.S. patient enrollment in the PARADIGM Trial reaches 100 patients or more.
Worry ifU.S. patient enrollment stalls or drops below 50 patients.
Why it matters: Securing new space is key for Anteris to support its operations and growth.
Supportive ifThe company has a new office and warehouse in Brooklyn Park, Minnesota.
Worry ifThe lease agreement is delayed or canceled. This affects operational plans.
Why it matters: Good news about payments can increase trial participation and boost investor trust.
Supportive ifManagement says more sites are active due to Medicare payments.
Worry ifNo new sites are active. Existing sites have negative feedback on payments.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$245 on $10,000 · ±2.5% | How much price usually moves either way. |
| Bad day | $610 loss on $10,000 · 6.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,677 loss on $10,000 · 46.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: CMS updates could affect patient recruitment and site use for the PARADIGM Trial.
Watch forCMS now covers more procedures from the PARADIGM Trial.
Also watch forIf CMS limits coverage, it will hurt recruitment efforts.
Why it matters: Ending this partnership could free up resources for better projects.
Worry ifA formal announcement says all development work with v2vmedtech has ended.
Less concerning ifThe company may keep working with v2vmedtech or change its decision to stop.
Why it matters: Financial results will show if Anteris is keeping costs down while running the PARADIGM Trial.
Watch forOperating cash outflows drop below $20 million. Revenue grows each year.
Also watch forOperating cash outflows go over $25 million with flat or falling revenue.
Why it matters: Better payments can increase patient sign-ups and site use for the PARADIGM Trial.
Supportive ifPatient sign-ups go up by 30% at U.S. sites in 3 months after payment changes.
Worry ifNo increase in patient enrollment at U.S. sites within 3 months after reimbursement updates.
Why it matters: The outcome will show if the company follows the rules. It will affect trading.
Watch forThe company will share good news about the Relief Application before August 4, 2026.
Also watch forThe company will share bad news or delays about the Relief Application.
Why it matters: Successful fundraising is key for paying for clinical trials and selling products.
Supportive ifNew capital raises of over $100 million are planned by Q4 2026.
Worry ifNo new capital raises announced by Q4 2026.
Why it matters: New clinical data can show DurAVR works well. This can attract more investors and doctors.
Supportive ifPositive results from the PARADIGM Trial will be shared at a big medical event.
Worry ifNegative or unclear results from the PARADIGM Trial will be presented.
Why it matters: New approvals can speed up patient recruitment and trial execution.
Supportive ifRegulatory approvals for more U.S. sites are given.
Worry ifNo new regulatory approvals are announced for U.S. sites.
Why it matters: This lease is a key step for Anteris to expand its operations. A successful move can improve efficiency and support growth.
Supportive ifThe company will use the new office and warehouse space by September 1, 2026.
Worry ifThe company delays or cancels the move to the new office and warehouse space.